Sarepta Therapeutics (NASDAQ:SRPT) Trading 8.8% Higher – Still a Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s share price traded up 8.8% on Wednesday . The stock traded as high as $17.35 and last traded at $17.1680. 568,266 shares were traded during mid-day trading, a decline of 80% from the average session volume of 2,885,650 shares. The stock had previously closed at $15.78.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a report on Tuesday, April 7th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a report on Thursday, April 16th. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a report on Tuesday, March 3rd. Oppenheimer reissued an “outperform” rating and issued a $37.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Eight research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $24.77.

Sarepta Therapeutics Price Performance

The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $18.93 and a two-hundred day moving average price of $19.69. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -18.49, a PEG ratio of 0.17 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.16 million. During the same period in the prior year, the firm earned ($3.42) EPS. The business’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 3.99 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after buying an additional 993,283 shares in the last quarter. AQR Capital Management LLC grew its holdings in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after buying an additional 6,390,860 shares in the last quarter. First Trust Advisors LP grew its holdings in Sarepta Therapeutics by 107.6% in the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after buying an additional 2,143,211 shares in the last quarter. Erste Asset Management GmbH grew its holdings in Sarepta Therapeutics by 1.6% in the 4th quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock worth $58,727,000 after buying an additional 43,000 shares in the last quarter. Finally, Aberdeen Group plc grew its holdings in Sarepta Therapeutics by 13.6% in the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after buying an additional 268,829 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.